Founding NewLink CEO Charles Link is out; Chi-Med lines up two more drug filings
→ Four years ago NewLink’s shares were riding high on the promise of IDO in oncology, trading at more than $50 a share …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
